Moreover, data from several trials in STEMI-ACS patients—GUSTO IV ACS [43], TIMI 11A [44], and FRISC (20)—showed that hs-CRP and Tnl were independent and complementary predictors of adverse clinical outcomes, including short- and long-term mortality, whereas the PROVE IT-TIMI 22 trial found that in a cohort of 4162 patients stabilized after ACS, patients with high hs-CRP values had a two-fold increase in the risk of new-onset or worsening HF during 2 years of follow-up [45]. This evidence concerns the gene CRP and hydrops fetalis.